| Cover Page - USD ($) $ in Millions | 12 Months Ended | ||
| Dec. 31, 2021 | Apr. 25, 2022 | Jun. 30, 2021 | |
| Document Information [Line Items] | |||
| Document Type | 10-K/A | ||
| Entity Registrant Name | Clarus Therapeutics Holdings, Inc. | ||
| Amendment Flag | true | ||
| Current Fiscal Year End Date | --12-31 | ||
| Document Period End Date | Dec. 31, 2021 | ||
| Document Fiscal Year Focus | 2021 | ||
| Document Fiscal Period Focus | FY | ||
| Entity Central Index Key | 0001817944 | ||
| Entity Filer Category | Non-accelerated Filer | ||
| Entity Small Business | true | ||
| Entity Emerging Growth Company | true | ||
| Entity Ex Transition Period | false | ||
| Entity Incorporation, State or Country Code | DE | ||
| Entity Current Reporting Status | Yes | ||
| Entity Voluntary Filers | No | ||
| Entity Well-known Seasoned Issuer | No | ||
| Entity Shell Company | false | ||
| Document Transition Report | false | ||
| Document Annual Report | true | ||
| Entity File Number | 001-39802 | ||
| Entity Tax Identification Number | 85-1231852 | ||
| Entity Interactive Data Current | Yes | ||
| ICFR Auditor Attestation Flag | false | ||
| Entity Address, Postal Zip Code | 60062 | ||
| Entity Address, Address Line One | 555 Skokie Boulevard | ||
| Entity Address, Address Line Two | Suite 340 | ||
| Entity Address, City or Town | Northbrook | ||
| Entity Address, State or Province | IL | ||
| City Area Code | 847 | ||
| Local Phone Number | 562-4300 | ||
| Entity Common Stock, Shares Outstanding | 24,750,011 | ||
| Entity Public Float | $ 25.6 | ||
| Auditor Name | RSM US LLP | ||
| Auditor Firm ID | 49 | ||
| Auditor Location | Chicago, Illinois | ||
| Amendment Description | Clarus Therapeutics Holdings, Inc. is filing this Amendment No. 1 to Annual Report on Form 10-K/A (“Amendment No. 1”) to amend its Annual Report on Form 10-K for the fiscal year ended December 31, 2021 (the “Form 10-K”) as filed with the Securities and Exchange Commission on March 31, 2022. The principal purpose of this Amendment No. 1 is to include the Part III information that was previously omitted from the Form 10-K in reliance on General Instruction G(3) to Form 10-K. Accordingly, this Amendment No. 1 hereby amends and restates Part III, Items 10 through 14 of the Form 10-K as set forth below and updates the Exhibits in Part IV, Item 15. No attempt has been made in this Amendment No. 1 to modify or update the other disclosures presented in the Form 10-K. This Amendment No. 1 does not reflect events occurring after the filing of the Form 10-K or modify or update those disclosures that may be affected by subsequent events. Accordingly, this Amendment No. 1 should be read in conjunction with the Form 10-K and our other filings with the SEC. In this report, unless otherwise stated or as the context otherwise requires, references to “Clarus,” “the Company,” “we,” “us,” “our” and similar references refer to Clarus Therapeutics Holdings, Inc. together with its consolidated subsidiary and references to “Legacy Clarus” refer to Clarus Therapeutics, Inc. prior to the completion of the Business Combination between Blue Water Acquisition Corp. and Legacy Clarus. The Clarus logo, JATENZO and other trademarks of Clarus Therapeutics Holdings, Inc. appearing in this Amendment No. 1 are the property of Clarus Therapeutics Holdings, Inc. This Amendment No. 1 also contains registered marks, trademarks and trade names of other companies. All other trademarks, registered marks and trade names appearing herein are the property of their respective holders. | ||
| Common Stock [Member] | |||
| Document Information [Line Items] | |||
| Trading Symbol | CRXT | ||
| Security Exchange Name | NASDAQ | ||
| Title of 12(g) Security | Common Stock, par value $0.0001 per share | ||
| Warrant [Member] | |||
| Document Information [Line Items] | |||
| Trading Symbol | CRXTW | ||
| Security Exchange Name | NASDAQ | ||
| Title of 12(g) Security | Warrants to purchase one share of common stock at an exercise price of $11.50. |
